tiprankstipranks
Definium Therapeutics, Inc. (DFTX)
NASDAQ:DFTX
US Market
DFTX
Definium Therapeutics
RESEARCH TOOLSreports
Want to see DFTX full AI Analyst Report?

Definium Therapeutics (DFTX) Stock Forecast & Price Target

2,421 Followers
See the Price Targets and Ratings of:

DFTX Analyst Ratings

Strong Buy
14Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Definium
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DFTX Stock 12 Month Forecast

Average Price Target

$65.93
▲(52.72% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Definium Therapeutics in the last 3 months. The average price target is $65.93 with a high forecast of $90.00 and a low forecast of $50.00. The average price target represents a 52.72% change from the last price of $43.17.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","28":"$28","49":"$49","70":"$70","91":"$91"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65.92857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$65.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,28,49,70,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.52,47.09538461538462,50.67076923076923,54.246153846153845,57.821538461538466,61.39692307692307,64.9723076923077,68.5476923076923,72.12307692307692,75.69846153846154,79.27384615384615,82.84923076923076,86.42461538461538,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.52,45.24373626373627,46.96747252747253,48.691208791208794,50.41494505494506,52.13868131868132,53.862417582417585,55.58615384615385,57.30989010989011,59.033626373626376,60.75736263736264,62.4810989010989,64.20483516483517,{"y":65.92857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.52,44.018461538461544,44.51692307692308,45.01538461538462,45.51384615384615,46.012307692307694,46.510769230769235,47.00923076923077,47.50769230769231,48.00615384615385,48.504615384615384,49.003076923076925,49.50153846153846,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.13,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.06,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$90.00Average Price Target$65.93Lowest Price Target$50.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DFTX
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$70
Buy
62.15%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Tenax Therapeutics (NASDAQ: TENX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
Jefferies Analyst forecast on DFTX
Andrew Tsai
Jefferies
Jefferies
$65
Buy
50.57%
Upside
Reiterated
08/13/26
Analysts' Top Healthcare Picks: MaxCyte (MXCT), Definium Therapeutics (DFTX)
JonesTrading Analyst forecast on DFTX
Justin Walsh
JonesTrading
JonesTrading
$74→$90
Buy
108.48%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Olympus (Other OTC: OCPNF), Journey Medical Corp (NASDAQ: DERM) and Definium Therapeutics (NASDAQ: DFTX)
Canaccord Genuity Analyst forecast on DFTX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$58→$64
Buy
48.25%
Upside
Reiterated
08/13/26
Canaccord Genuity Remains a Buy on Definium Therapeutics (DFTX)
Wells Fargo Analyst forecast on DFTX
Benjamin Burnett
Wells Fargo
Wells Fargo
$68→$72
Buy
66.78%
Upside
Reiterated
08/13/26
Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo
Needham Analyst forecast on DFTX
Ami Fadia
Needham
Needham
$50→$66
Buy
52.88%
Upside
Reiterated
08/12/26
Ami Fadia Reiterates Buy on Definium (DFTX) as Strong Phase 3 VOYAGE Data Support Unchanged $50 Price Target
RBC Capital Analyst forecast on DFTX
Brian Abrahams
RBC Capital
RBC Capital
$57→$66
Buy
52.88%
Upside
Assigned
08/12/26
RBC Capital Sticks to Their Buy Rating for Definium Therapeutics (DFTX)
LifeSci Capital Analyst forecast on DFTX
Francois Brisebois
LifeSci Capital
LifeSci Capital
$63→$75
Buy
73.73%
Upside
Reiterated
08/12/26
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Eli Lilly & Co (LLY)
Evercore ISI Analyst forecast on DFTX
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$53
Buy
22.77%
Upside
Reiterated
08/10/26
Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)
Oppenheimer Analyst forecast on DFTX
Jay Olson
Oppenheimer
Oppenheimer
$60
Buy
38.99%
Upside
Reiterated
08/07/26
Definium Therapeutics (DFTX) Receives a Buy from Oppenheimer
Piper Sandler Analyst forecast on DFTX
David Amsellem
Piper Sandler
Piper Sandler
$73→$75
Buy
73.73%
Upside
Reiterated
08/07/26
Piper Sandler Remains a Buy on Definium Therapeutics (DFTX)
Stifel Nicolaus Analyst forecast on DFTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$60
Buy
38.99%
Upside
Reiterated
08/07/26
Definium Therapeutics (DFTX) Gets a Buy from Stifel Nicolaus
Robert W. Baird Analyst forecast on DFTX
Christopher Chen
Robert W. Baird
Robert W. Baird
$37→$57
Buy
32.04%
Upside
Reiterated
06/23/26
Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird
Maxim Group Analyst forecast on DFTX
Michael Okunewitch
Maxim Group
Maxim Group
$40→$50
Buy
15.82%
Upside
Assigned
06/23/26
Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment
Wolfe Research Analyst forecast on DFTX
Rudy Li
Wolfe Research
Wolfe Research
$25
Buy
-42.09%
Downside
Initiated
02/23/26
Definium Therapeutics initiated with an Outperform at Wolfe ResearchDefinium Therapeutics initiated with an Outperform at Wolfe Research
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DFTX
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$70
Buy
62.15%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX), Tenax Therapeutics (NASDAQ: TENX) and MoonLake Immunotherapeutics (NASDAQ: MLTX)
Jefferies Analyst forecast on DFTX
Andrew Tsai
Jefferies
Jefferies
$65
Buy
50.57%
Upside
Reiterated
08/13/26
Analysts' Top Healthcare Picks: MaxCyte (MXCT), Definium Therapeutics (DFTX)
JonesTrading Analyst forecast on DFTX
Justin Walsh
JonesTrading
JonesTrading
$74→$90
Buy
108.48%
Upside
Reiterated
08/13/26
Analysts Offer Insights on Healthcare Companies: Olympus (Other OTC: OCPNF), Journey Medical Corp (NASDAQ: DERM) and Definium Therapeutics (NASDAQ: DFTX)
Canaccord Genuity Analyst forecast on DFTX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$58→$64
Buy
48.25%
Upside
Reiterated
08/13/26
Canaccord Genuity Remains a Buy on Definium Therapeutics (DFTX)
Wells Fargo Analyst forecast on DFTX
Benjamin Burnett
Wells Fargo
Wells Fargo
$68→$72
Buy
66.78%
Upside
Reiterated
08/13/26
Definium Therapeutics (DFTX) Receives a Buy from Wells Fargo
Needham Analyst forecast on DFTX
Ami Fadia
Needham
Needham
$50→$66
Buy
52.88%
Upside
Reiterated
08/12/26
Ami Fadia Reiterates Buy on Definium (DFTX) as Strong Phase 3 VOYAGE Data Support Unchanged $50 Price Target
RBC Capital Analyst forecast on DFTX
Brian Abrahams
RBC Capital
RBC Capital
$57→$66
Buy
52.88%
Upside
Assigned
08/12/26
RBC Capital Sticks to Their Buy Rating for Definium Therapeutics (DFTX)
LifeSci Capital Analyst forecast on DFTX
Francois Brisebois
LifeSci Capital
LifeSci Capital
$63→$75
Buy
73.73%
Upside
Reiterated
08/12/26
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Eli Lilly & Co (LLY)
Evercore ISI Analyst forecast on DFTX
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$53
Buy
22.77%
Upside
Reiterated
08/10/26
Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)
Oppenheimer Analyst forecast on DFTX
Jay Olson
Oppenheimer
Oppenheimer
$60
Buy
38.99%
Upside
Reiterated
08/07/26
Definium Therapeutics (DFTX) Receives a Buy from Oppenheimer
Piper Sandler Analyst forecast on DFTX
David Amsellem
Piper Sandler
Piper Sandler
$73→$75
Buy
73.73%
Upside
Reiterated
08/07/26
Piper Sandler Remains a Buy on Definium Therapeutics (DFTX)
Stifel Nicolaus Analyst forecast on DFTX
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$60
Buy
38.99%
Upside
Reiterated
08/07/26
Definium Therapeutics (DFTX) Gets a Buy from Stifel Nicolaus
Robert W. Baird Analyst forecast on DFTX
Christopher Chen
Robert W. Baird
Robert W. Baird
$37→$57
Buy
32.04%
Upside
Reiterated
06/23/26
Definium Therapeutics price target raised to $57 from $37 at BairdDefinium Therapeutics price target raised to $57 from $37 at Baird
Maxim Group Analyst forecast on DFTX
Michael Okunewitch
Maxim Group
Maxim Group
$40→$50
Buy
15.82%
Upside
Assigned
06/23/26
Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment
Wolfe Research Analyst forecast on DFTX
Rudy Li
Wolfe Research
Wolfe Research
$25
Buy
-42.09%
Downside
Initiated
02/23/26
Definium Therapeutics initiated with an Outperform at Wolfe ResearchDefinium Therapeutics initiated with an Outperform at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
ACRVAcrivon Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Definium Therapeutics

3 Months
Ami FadiaNeedham
Success Rate
7/8 ratings generated profit
88%
Average Return
+46.00%
Copying Ami Fadia's trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +46.00% per trade.
1 Year
Patrick TrucchioH.C. Wainwright
Success Rate
16/18 ratings generated profit
89%
Average Return
+131.13%
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +131.13% per trade.
2 Years
Patrick TrucchioH.C. Wainwright
Success Rate
18/18 ratings generated profit
100%
Average Return
+289.89%
Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +289.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DFTX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
25
31
36
22
20
Buy
6
4
11
9
18
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
35
47
31
38
In the current month, DFTX has received 38 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. DFTX average Analyst price target in the past 3 months is 65.93.
Each month's total comprises the sum of three months' worth of ratings.

DFTX Financial Forecast

DFTX Earnings Forecast

Next quarter’s earnings estimate for DFTX is -$0.55 with a range of -$0.68 to -$0.45. The previous quarter’s EPS was -$1.44. DFTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for DFTX is -$0.55 with a range of -$0.68 to -$0.45. The previous quarter’s EPS was -$1.44. DFTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.
No data currently available

DFTX Sales Forecast

Next quarter’s sales forecast for DFTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DFTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.
Next quarter’s sales forecast for DFTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. DFTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DFTX has Performed in-line its overall industry.

DFTX Stock Forecast FAQ

What is DFTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Definium Therapeutics, Inc.’s 12-month average price target is 65.93.
    What is DFTX’s upside potential, based on the analysts’ average price target?
    Definium Therapeutics, Inc. has 52.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DFTX a Buy, Sell or Hold?
          Definium Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Definium Therapeutics, Inc.’s price target?
            The average price target for Definium Therapeutics, Inc. is 65.93. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $90.00 ,the lowest forecast is $50.00. The average price target represents 52.72% Increase from the current price of $43.17.
              What do analysts say about Definium Therapeutics, Inc.?
              Definium Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of DFTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.